Tau Archives -

Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one

AC Immune claims half a win for tau drug in Alzheimer’s trial

https://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/

Just a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

https://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/

Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them –

Biogen abandons tau antibody for Alzheimer’s after phase 2 miss

https://pharmaphorum.com/news/biogen-abandons-tau-antibody-for-alzheimers-after-phase-2-miss/

Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s

Early data back J&J and AC Immune’s Alzheimer’s jab

https://pharmaphorum.com/news/early-data-back-jj-and-ac-immunes-alzheimers-jab/

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a

AC Immune poleaxed on Alzheimer’s study fail

https://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a

Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m

https://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/

Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare

A bright future for CNS and Alzheimer’s?

https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/

Tau